Seattle startup raises $5M; QRx snags commercialization deal; GenVec hunts for new CEO;

@FierceBiotech: Tiny robots may be next big drug-delivery thing. News | Follow @FierceBiotech

@JohnCFierce: A struggling AstraZeneca commits $140M to cancer pact as it inks back-to-back deals. Story | Follow@JohnCFierce

@RyanMFierce: Takeda doesn't say how many jobs will be impacted in the move to consolidate in San Diego. Release | Follow @RyanMFierce

@MarkHFierce: Perosphere debuts! It has connections with Brown, Harvard and MIT, among others. Article | Follow @MarkHFierce

Xconomy reports that Seattle entrepreneur Bruce Montgomery has rounded up $5 million in venture backing for Cardeas, a startup developer. Story

> Australia's QRx Pharma has struck a deal that gives Actavis U.S. commercialization rights to the pain drug MoxDuo IR. QRx snagged a $6 million upfront in the deal. Release

> GenVec CEO Paul Fischer, Ph.D., is retiring from his post. The biotech has hired a search firm to help out with recruiting a new chief executive. Release

Pharma News

@FiercePharma: EU reins in exports of lethal-injection drugs, barring sale in countries still using death penalty. News | Follow @FiercePharma

> EU imposes new export controls on execution meds. News

> Ranbaxy inks consent decree, sets aside $500M. Item

> FDA joins probe into Gilenya patient's sudden death. More

Drug Delivery News

> Pfizer to employ Antares drug-delivery tech for mystery product. News

> Perosphere launches with Brown, Harvard and MIT connections. Article

> Say it with lollipops to treat oral thrush. Item

> Eli Lilly advances drug delivery tech deals with Starpharma, Arecor. Story

Biomarkers News

> Biomarker predicts tamoxifen breast cancer response. More

> Urinary serotonin may be key to test for depression. Story

> MicroRNA can help guide cancer treatment. News

> Biomarker predicts tamoxifen breast cancer response. Report

Medical Device News

> Philips, Steris to add 200 jobs in Ohio. Article

> Report: GE plans to add 200 engineers in China. Story

> Bard picks up Lutonix for $225M. More

 

And Finally... Scientists at the Salk Institute say they discovered a "missing link" between the body's biological clock and sugar metabolism system, pointing the way to possibly eliminating some of the side effects associated with therapies for asthma, allergies and arthritis. Release

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.